study cancelled prior to FSI

24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance. If the subject does not reach the EAS LDL-C treatment goal at week 12, rosuvastatin will be titrated from 10mg to 20mg.

Inclusion Criteria:

• Primary hypercholesterolaemia:
• Statin naïve subjects (LDL-C level > 3.5 mmol/L) or subjects on an ineffective "start dose" of a lipid-lowering therapy (LDL-C level > 3.1 mmol/L).
• CV risk > 20%,
• history of CHD or other established atherosclerotic disease

Exclusion Criteria:

• History of severe adverse events with another HMG-CoA reductase inhibitor
• Secondary hypercholesterolaemia;
• Unstable cardiovascular disease;
• Uncontrolled diabetes, active liver disease;
• Severe hepatic or renal impairment;
• Treatment with cyclosporin.